0001209191-20-056981.txt : 20201104 0001209191-20-056981.hdr.sgml : 20201104 20201104180909 ACCESSION NUMBER: 0001209191-20-056981 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201102 FILED AS OF DATE: 20201104 DATE AS OF CHANGE: 20201104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BENEVICH ERIC CENTRAL INDEX KEY: 0001643653 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 201288019 MAIL ADDRESS: STREET 1: C/O NEUROCRINE BIOSCIENCES, INC. STREET 2: 12790 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-02 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001643653 BENEVICH ERIC 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Commercial Officer Common Stock 2020-11-02 4 M 0 20595 35.99 A 35969 D Common Stock 2020-11-02 4 S 0 20595 96.5269 D 15374 D Non-Qualified Stock Option 35.99 2020-11-02 4 M 0 20595 35.99 D 2026-02-05 Common Stock 20595 7775 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $94.68 to $98.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Option granted February 05, 2016 and vested monthly over four years. /s/ Darin Lippoldt, Attorney-in-Fact 2020-11-04